Helus Pharma Appoints Former Pfizer CMO Dr. Freda Lewis-Hall to Board and Scientific Advisory Chair
HELP sits 53% above its 52-week low of $4.81.
Summary
Helus Pharma, operating as Cybin Inc., has appointed Dr. Freda Lewis-Hall, former Pfizer Chief Medical Officer, to its Board of Directors and as Chair of its Scientific Advisory Committee, significantly bolstering its clinical and regulatory expertise.
Key Events · Executive and Board Changes · HELP
-
High-Profile Board Appointment
Dr. Freda Lewis-Hall, a distinguished physician and biopharmaceutical executive, has been appointed to Helus Pharma's Board of Directors.
-
Scientific Advisory Committee Leadership
Dr. Lewis-Hall will also serve as Chair of the Company's Scientific Advisory Committee, guiding clinical development and regulatory strategy.
-
Extensive Industry Experience
Her background includes over a decade as Executive Vice President and Chief Medical Officer at Pfizer, as well as senior leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, and Eli Lilly and Company.
-
Strategic Enhancement for Clinical-Stage Company
This appointment is crucial for a clinical-stage pharmaceutical company like Helus Pharma, providing invaluable expertise in advancing its novel serotonergic agonist (NSA) portfolio for mental health conditions.
Analysis · HELP · Life Sciences
The appointment of Dr. Freda Lewis-Hall, a former Chief Medical Officer at Pfizer and a seasoned biopharmaceutical executive, to both the Board of Directors and as Chair of the Scientific Advisory Committee is a highly significant development for Helus Pharma (Cybin Inc.). Her extensive experience in clinical development, regulatory engagement, and global commercialization, particularly in mental health, provides a substantial boost to the company's credibility and strategic capabilities. This move follows recent positive Phase 2a clinical trial results and a substantial $175 million financing round, indicating a strategic focus on strengthening leadership to advance its novel serotonergic agonist (NSA) pipeline and execute on its growth plans.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.7% of the 1872 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HELP was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.81 to $9.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.